MET signalling: Principles and functions in development, organ regeneration and cancer

Nature Reviews Molecular Cell Biology

Volumn 11, Issue 12, 2010, Pages 834-848

  Trusolino, Livio ^a   Bertotti, Andrea ^a   Comoglio, Paolo M ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CD44V6 ANTIGEN; CD45 ANTIGEN; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE; PROTEIN TYROSINE PHOSPHATASE; RAF PROTEIN; SCAFFOLD PROTEIN; SCATTER FACTOR RECEPTOR; SEMAPHORIN; STAT PROTEIN; TYROSINE KINASE RECEPTOR;

CANCER GROWTH; CELL MIGRATION; CYTOSKELETON; DOWN REGULATION; EMBRYO DEVELOPMENT; ENDOTHELIUM CELL; INTERNALIZATION; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; TISSUE REGENERATION; UBIQUITINATION;

ANIMAL STRUCTURES; ANIMALS; GROWTH AND DEVELOPMENT; HUMANS; MODELS, BIOLOGICAL; MODELS, MOLECULAR; NEOPLASMS; PROTO-ONCOGENE PROTEINS C-MET; REGENERATION; SIGNAL TRANSDUCTION;

EID: 78649420006     PISSN: 14710072     EISSN: 14710080     Source Type: Journal    
DOI: 10.1038/nrm3012     Document Type: Review

References (169)

1. Bryant, D. M. & Mostov, K. E. From cells to organs: building polarized tissue. Nature Rev. Mol. Cell Biol. 9, 887-901 (2008).
2. Gurtner, G. C., Werner, S., Barrandon, Y. & Longaker, M. T. Wound repair and regeneration. Nature 453, 314-321 (2008).
3. Frisch, S. M. & Screaton, R. A. Anoikis mechanisms. Curr. Opin. Cell Biol. 13, 555-562 (2001).
4. Lu, P. & Werb, Z. Patterning mechanisms of branched organs. Science 322, 1506-1509 (2008).
5. Zaret, K. S. & Grompe, M. Generation and regeneration of cells of the liver and pancreas. Science 322, 1490-1494 (2008).
6. Schäfer, M. & Werner, S. Cancer as an overhealing wound: an old hypothesis revisited. Nature Rev. Mol. Cell Biol. 9, 628-638 (2008).
7. Yang, J. & Weinberg, R. A. Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Dev. Cell 14, 818-829 (2008).
8. Christofori, G. New signals from the invasive front. Nature 441, 444-450 (2006).
9. Kalluri, R. & Weinberg, R. A. The basics of epithelial-mesenchymal transition. J. Clin. Invest. 11 9, 1420-1428 (2009).
10. Thiery, J. P., Acloque, H., Huang, R. Y. & Nieto, M. A. Epithelial-mesenchymal transitions in development and disease. Cell 139, 871-890 (2009).
11. Park, M. et al. Mechanism of met oncogene activation. Cell 45, 895-904 (1986).
12. Giordano, S., Ponzetto, C., Di Renzo, M. F., Cooper, C. S. & Comoglio, P. M. Tyrosine kinase receptor indistinguishable from the c-met protein. Nature 339, 155-156 (1989).
13. Stoker, M., Gherardi, E., Perryman, M. & Gray, J. Scatter factor is a fibroblast-derived modulator of epithelial cell motility. Nature 327, 239-242 (1987).
14. Nakamura, T. et al. Molecular cloning and expression of human hepatocyte growth factor. Nature 342, 440-443 (1989).
15. Zarnegar, R. & Michalopoulos, G. Purification and biological characterization of human hepatopoietin A, A polypeptide growth factor for hepatocytes. Cancer Res. 49, 3314-3320 (1989).
16. Bottaro, D. P. et al. Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science 251, 802-804 (1991).
17. Montesano, R., Matsumoto, K., Nakamura, T. & Orci, L. Identification of a fibroblast-derived epithelial morphogen as hepatocyte growth factor. Cell 67, 901-908 (1991).
18. Naldini, L. et al. Hepatocyte growth factor (HGF) stimulates the tyrosine kinase activity of the receptor encoded by the proto-oncogene c-MET. Oncogene 6, 501-504 (1991).
19. Naldini, L. et al. Scatter factor and hepatocyte growth factor are indistinguishable ligands for the MET receptor. EMBO J. 10, 2867-2878 (1991).
20. Weidner, K. M. et al. Evidence for the identity of human scatter factor and human hepatocyte growth factor. Proc. Natl Acad. Sci. USA 88, 7001-7005 (1991).
21. Birchmeier, C. & Gherardi, E. Developmental roles of HGF/SF and its receptor, The c-Met tyrosine kinase. Trends Cell Biol. 8, 404-410 (1998).
22. Birchmeier, C., Birchmeier, W., Gherardi, E. & Vande Woude, G. F. Met, Metastasis, Motility and more. Nature Rev. Mol. Cell Biol. 4, 915-925 (2003).
23. Comoglio, P. M., Giordano, S. & Trusolino, L. Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nature Rev. Drug Discov. 7, 504-516 (2008).
24. Trusolino, L. & Comoglio, P. M. Scatter-factor and semaphorin receptors: cell signalling for invasive growth. Nature Rev. Cancer 2, 289-300 (2002).
25. Lai, A. Z., Abella, J. V. & Park, M. Crosstalk in Met receptor oncogenesis. Trends Cell Biol. 19, 542-551 (2009).
26. Furge, K. A., Zhang, Y. W. & Vande Woude, G. F. Met receptor tyrosine kinase: enhanced signaling through adapter proteins. Oncogene 19, 5582-5589 (2000).
27. Zhang, Y. W. & Vande Woude, G. F. HGF/SF-met signaling in the control of branching morphogenesis and invasion. J. Cell. Biochem. 88, 408-417 (2003).
28. Gao, C. F. & Vande Woude, G. F. HGF/SF-Met signaling in tumor progression. Cell Res. 15, 49-51 (2005).
29. Peschard, P. & Park, M. From Tpr-Met to Met, Tumorigenesis and tubes. Oncogene 26, 1276-1285 (2007).
30. Kobayashi, T. et al. Hepatocyte growth factor specifically binds to sulfoglycolipids. J. Biol. Chem. 269, 9817-9821 (1994).
31. Lyon, M., Deakin, J. A., Mizuno, K., Nakamura, T. & Gallagher, J. T. Interaction of hepatocyte growth factor with heparan-sulfate. Elucidation of the major heparan sulfate structural determinants. J. Biol. Chem. 269, 11216-11223 (1994).
32. Sonnenberg, E., Meyer, D., Weidner, K. M. & Birchmeier, C. Scatter factor/hepatocyte growth factor and its receptor, The c-met tyrosine kinase, Can mediate a signal exchange between mesenchyme and epithelia during mouse development. J. Cell Biol. 123, 223-235 (1993).
33. Michalopoulos, G. K. & DeFrances, M. C. Liver regeneration. Science 276, 60-66 (1997).
34. Bhowmick, N. A., Neilson, E. G. & Moses, H. L. Stromal fibroblasts in cancer initiation and progression. Nature 432, 332-337 (2004).
35. Mars, W. M., Zarnegar, R. & Michalopoulos, G. K. Activation of hepatocyte growth factor by the plasminogen activators uPA and tPA. Am. J. Pathol. 143, 949-958 (1993).
36. Owen, K. A. et al. Pericellular activation of hepatocyte growth factor by the transmembrane serine proteases matriptase and hepsin, But not by the membrane-associated protease uPA. Biochem. J. 426, 219-228 (2010).
37. Ponzetto, C. et al. A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family. Cell 77, 261-271 (1994).
38. Palka, H. L., Park, M. & Tonks, N. K. Hepatocyte growth factor receptor tyrosine kinase met is a substrate of the receptor protein-tyrosine phosphatase DEP-1. J. Biol. Chem. 278, 5728-5735 (2003).
39. Machide, M., Hashigasako, A., Matsumoto, K. & Nakamura, T. Contact inhibition of hepatocyte growth regulated by functional association of the c-Met/ hepatocyte growth factor receptor and LAR protein-tyrosine phosphatase. J. Biol. Chem. 281, 8765-8772 (2006).
40. Sangwan, V. et al. Regulation of the Met receptor-tyrosine kinase by the protein-tyrosine phosphatase 1B and T-cell phosphatase. J. Biol. Chem. 283, 34374-34383 (2008).
41. Bertotti, A. & Comoglio, P. M. Tyrosine kinase signal specificity: lessons from the HGF receptor. Trends Biochem. Sci. 28, 527-533 (2003).
42. Sipeki, S. et al. Phosphatidylinositol 3-kinase contributes to Erk1/Erk2 MAP kinase activation associated with hepatocyte growth factor-induced cell scattering. Cell Signal. 11, 885-890 (1999).
43. Maroun, C. R. et al. The Gab1 PH domain is required for localization of Gab1 at sites of cell-cell contact and epithelial morphogenesis downstream from the met receptor tyrosine kinase. Mol. Cell. Biol. 19, 1784-1799 (1999).
44. Maroun, C. R., Naujokas, M. A., Holgado-Madruga, M., Wong, A. J. & Park, M. The tyrosine phosphatase SHP-2 is required for sustained activation of extracellular signal-regulated kinase and epithelial morphogenesis downstream from the met receptor tyrosine kinase. Mol. Cell. Biol. 20, 8513-8525 (2000).
45. Pelicci, G. et al. The motogenic and mitogenic responses to HGF are amplified by the Shc adaptor protein. Oncogene 10, 1631-1638 (1995).
46. Fixman, E. D., Fournier, T. M., Kamikura, D. M., Naujokas, M. A. & Park M. Pathways downstream of Shc and Grb2 are required for cell transformation by the Tpr-Met oncoprotein J. Biol. Chem. 271, 13116-13122 (1996).
47. Boccaccio, C. et al. Induction of epithelial tubules by growth factor HGF depends on the STAT pathway Nature 391, 285-288 (1998).
48. Zhang, Y. W., Wang, L. M., Jove, R. & Vande Woude, G. F Requirement of Stat3 signaling for HGF/SF-Met mediated tumorigenesis. Oncogene 21, 217-226 (2002).
49. Weidner, K. M. et al. Interaction between Gab1 and the c-Met receptor tyrosine kinase is responsible for epithelial morphogenesis. Nature 384, 173-176 (1996).
50. Garcia-Guzman, M., Dolfi, F, Zeh, K. & Vuori, K. Met-induced JNK activation is mediated by the adapter protein Crk and correlates with the Gab 1 -Crk signaling complex formation. Oncogene 18, 7775-7786 (1999).
51. Schaeper, U. et al. Coupling of Gab 1 to c-Met, Grb2, And Shp2 mediates biological responses. J. Cell Biol. 149, 1419-1432 (2000).
52. Gual, P. et al. Sustained recruitment of phospholipase c-y to Gab 1 is required for HGF-induced branching tubulogenesis. Oncogene 19, 1509-1518 (2000).
53. Montagner, A. et al. A novel role for Gab 1 and SHP2 in epidermal growth factor-induced Ras activation. J. Biol. Chem. 280, 5350-5360 (2005).
54. Lock, L. S., Royal, I., Naujokas, M. A. & Park, M. Identification of an atypical Grb2 carboxyl-terminal SH3 domain binding site in Gab docking proteins reveals Grb2-dependent and -independent recruitment of Gab 1 to receptor tyrosine kinases. J. Biol. Chem. 275, 31536-31545 (2000).
55. Comoglio, P. M., Boccaccio, C. & Trusolino, L Interactions between growth factor receptors and adhesion molecules: breaking the rules. Curr. Opin. Cell Biol. 15, 565-571 (2003).
56. Trusolino, L, Bertotti, A. & Comoglio, P. M. A signaling adapter function for a6(34 integrin in the control of HGF-dependent invasive growth. Cell 107, 643-654 (2001).
57. Bertotti, A., Comoglio, P. M. & Trusolino, L. (34 integrin is a transforming molecule that unleashes Met tyrosine kinase tumorigenesis. Cancer Res. 65, 10674-10679 (2005).
58. Bertotti, A., Comoglio, P. M. & Trusolino, L. (34 integrin activates a Shp2-Src signaling pathway that sustains HGF-induced anchorage-independent growth. J. Cell Biol. 175, 993-1003 (2006).
59. Ponta, H., Sherman, L. & Herrlich, P. A. CD44: from adhesion molecules to signalling regulators. Nature Rev. Mol. Cell Biol. 4, 33-45 (2003).
60. Orian-Rousseau, V, Chen, L, Sleeman, J. P., Herrlich, P. & Ponta, H. CD44 is required for two consecutive steps in HGF/c-Met signaling. Genes Dev. 16, 3074-3086 (2002).
61. Orian-Rousseau, V. et al. Hepatocyte growth factor-induced Ras activation requires ERM proteins linked to both CD44v6 and F-actin. Mol. Biol. Cell 18, 76-83 (2007).
62. Singleton, P. A. et al. CD44 regulates hepatocyte growth factor-mediated vascular integrity. Role of c-Met, Tiam1/Rac1, Dynamin 2, And cortactin. J. Biol. Chem. 282, 30643-30657 (2007).
63. Giordano, S. et al. The semaphorin 4D receptor controls invasive growth by coupling with Met. Nature Cell Biol. 4, 720-724 (2002).
64. Conrotto, P., Corso, S., Gamberini, S., Comoglio, P. M. & Giordano, S. Interplay between scatter factor receptors and B plexins controls invasive growth. Oncogene 23, 5131-5137 (2004).
65. Conrotto, P. et al. Sema4D induces angiogenesis through Met recruitment by Plexin B1. Blood 105, 4321-4329 (2005).
66. Capparuccia, L. & Tamagnone, L. Semaphorin signaling in cancer cells and in cells of the tumor microenvironment - two sides of a coin. J. Cell Sci. 122, 1723-1736 (2009).
67. Johnson, G. L. & Lapadat, R. Mitogen-activated protein kinase pathways mediated by ERK, JNK, And p38 protein kinases. Science 298, 1911-1912 (2002).
68. Stella, M. C., Trusolino, L., Pennacchietti, S. & Comoglio, P. M. Negative feedback regulation of Met-dependent invasive growth by Notch. Mol. Cell. Biol. 25, 3982-3996 (2005).
69. Lee, C. C. et al. Overexpression of sprouty 2 inhibits HGF/SF-mediated cell growth, Invasion, Migration, And cytokinesis. Oncogene 23, 5193-5202 (2004).
70. Rodrigues, G. A., Park, M. & Schlessinger, J. Activation of the JNK pathway is essential for transformation by the Met oncogene. EMBO J. 16, 2634-2645 (1997).
71. Lamorte, L., Kamikura, D. M. & Park, M. A switch from p130Cas/Crk to Gab1/Crk signaling correlates with anchorage independent growth and JNK activation in cells transformed by the Met receptor oncoprotein. Oncogene 19, 5973-5981 (2000).
72. Recio, J. A. & Merlino, G. Hepatocyte growth factor/ scatter factor activates proliferation in melanoma cells through p38 MAPK, ATF-2 and cyclin D1. Oncogene 21, 1000-1008 (2002).
73. Rasola, A. et al. Hepatocyte growth factor sensitizes human ovarian carcinoma cell lines to paclitaxel and cisplatin. Cancer Res. 64, 1744-1750 (2004).
74. Coltella, N. et al. p38 MAPK turns hepatocyte growth factor to a death signal that commits ovarian cancer cells to chemotherapy-induced apoptosis. Int. J. Cancer 11 8, 2981-2990 (2006).
75. Karin, M., Cao, Y., Greten, F. R. & Li, Z. W. NF-κB in cancer: from innocent bystander to major culprit. Nature Rev. Cancer 2, 301-310 (2002).
76. Fan, S. et al. Role of NF-κB signaling in hepatocyte growth factor/scatter factor-mediated cell protection. Oncogene 24, 1749-1766 (2005).
77. Müller, M., Morotti, A. & Ponzetto, C. Activation of NF-κB is essential for hepatocyte growth factor-mediated proliferation and tubulogenesis. Mol. Cell. Biol. 22, 1060-1072 (2002).
78. Scita, G. & Di Fiore, P. P. The endocytic matrix. Nature 463, 464-473 (2010).
79. Kermorgant, S. & Parker, P. J. c-Met signaling: spatiotemporal decisions. Cell Cycle 4, 352-355 (2005).
80. Liu, Z. X., Yu, C. F., Nickel, C., Thomas, S. & Cantley, L. G. Hepatocyte growth factor induces ERK-dependent paxillin phosphorylation and regulates paxillin-focal adhesion kinase association. J. Biol. Chem. 277, 10452-10458 (2002).
81. Kermorgant, S., Zicha, D. & Parker, P. J. PKC controls HGF-dependent c-Met traffic, Signalling and cell migration. EMBO J. 23, 3721-3734 (2004).
82. Rosse, C. et al. PKC and the control of localized signal dynamics. Nature Rev. Mol. Cell Biol. 11, 103-112 (2010).
83. Kermorgant, S., Zicha, D. & Parker, P. J. Protein kinase C controls microtubule-based traffic but not proteasomal degradation of c-Met. J. Biol. Chem. 278, 28921-28929 (2003).
84. Kermorgant, S. & Parker, P. J. Receptor trafficking controls weak signal delivery: a strategy used by c-Met for STAT3 nuclear accumulation. J. Cell Biol. 182, 855-863 (2008).
85. Sorkin, A. & von Zastrow, M. Endocytosis and signalling: intertwining molecular networks. Nature Rev. Mol. Cell Biol. 10, 609-622 (2009).
86. Peschard, P. et al. Mutation of the c-Cbl TKB domain binding site on the Met receptor tyrosine kinase converts it into a transforming protein. Mol. Cell 8, 995-1004 (2001).
87. Carter, S., Urbé, S. & Clague, M. J. The met receptor degradation pathway: requirement for Lys48-linked polyubiquitin independent of proteasome activity. J. Biol. Chem. 279, 52835-52839 (2004).
88. Hammond, D. E., Urbé, S., Vande Woude, G. F. & Clague, M. J. Down-regulation of Met, The receptor for hepatocyte growth factor. Oncogene 20, 2761-2770 (2001).
89. Li, N., Xiang, G. S., Dokainish, H., Ireton, K. & Elferink, L. A. The Listeria protein internalin B mimics hepatocyte growth factor-induced receptor trafficking. Traffic 6, 459-473 (2005).
90. Oved, S. & Yarden, Y. Signal transduction: molecular ticket to enter cells. Nature 416, 133-136 (2002).
91. Petrelli, A. et al. The endophilin-CIN85-Cbl complex mediates ligand-dependent downregulation of c-Met. Nature 416, 187-190 (2002).
92. Goldoni, S. et al. Decorin is a novel antagonistic ligand of the Met receptor. J. Cell Biol. 185, 743-754 (2009).
93. Polo, S. & Di Fiore, P. P. Endocytosis conducts the cell signaling orchestra. Cell 124, 897-900 (2006).
94. Foveau, B. et al. Down-regulation of the met receptor tyrosine kinase by presenilin-dependent regulated intramembrane proteolysis. Mol. Biol. Cell. 20, 2495-2507 (2009).
95. Prat, M. et al. C-terminal truncated forms of Met, The hepatocyte growth factor receptor. Mol. Cell. Biol. 11, 5954-5962 (1991).
96. Galvani, A. P., Cristiani, C., Carpinelli, P., Landonio, A. & Bertolero, F. Suramin modulates cellular levels of hepatocyte growth factor receptor by inducing shedding of a soluble form. Biochem. Pharmacol. 50, 959-966 (1995).
97. Nath, D., Williamson, N. J., Jarvis, R. & Murphy, G. Shedding of c-Met is regulated by crosstalk between a G-protein coupled receptor and the EGF receptor and is mediated by a TIMP-3 sensitive metalloproteinase. J. Cell Sci. 11 4, 1213-1220 (2001).
98. Wajih, N., Walter, J. & Sane, D. C. Vascular origin of a soluble truncated form of the hepatocyte growth factor receptor (c-met). Circ. Res. 90, 46-52 (2002).
99. Petrelli, A. et al. Ab-induced ectodomain shedding mediates hepatocyte growth factor receptor down-regulation and hampers biological activity. Proc. Natl Acad. Sci. USA 103, 5090-5095 (2006).
100. Schelter, F. et al. A disintegrin and metalloproteinase-10 (ADAM-10) mediates DN30 antibody-induced shedding of the met surface receptor. J. Biol. Chem. 285, 26335-26340 (2010).
101. Vigna, E. et al. "Active" cancer immunotherapy by anti-Met antibody gene transfer. Cancer Res. 68, 9176-9183 (2008).
102. Pacchiana, G. et al. Monovalency unleashes the full therapeutic potential of the DN-30 anti-Met antibody. J. Biol. Chem. 285, 36149-36157 (2010).
103. Michieli, P. et al. Targeting the tumor and its microenvironment by a dual-function decoy Met receptor. Cancer Cell 6, 61-73 (2004).
104. Zhang, Y. W., Graveel, C., Shinomiya, N. & Vande Woude, G. F. Met decoys: will cancer take the bait? Cancer Cell 6, 5-6 (2004).
105. Barabasi, A.-L. & Oltavi, Z. N. Network biology: understanding the cell's functional organization. Nature Rev. Genet. 5, 101-113 (2004).
106. Schmidt, C. et al. Scatter factor/hepatocyte growth factor is essential for liver development. Nature 373, 699-702 (1995).
107. Uehara, Y. et al. Placental defect and embryonal lethality in mice lacking hepatocyte growth factor/ scatter factor. Nature 373, 702-705 (1995).
108. Bladt, F., Riethmacher, D., Isenmann, S., Aguzzi, A. & Birchmeier, C. Essential role for the c-met receptor in the migration of myogenic precursor cells into the limb bud. Nature 376, 768-771 (1995).
109. Birchmeier, C. & Gherardi, E. Developmental roles of HGF/SF and its receptor, The c-Met tyrosine kinase. Trends Cell Biol. 8, 404-410 (1998).
110. Maina, F., Hilton, M. C., Ponzetto, C., Davies, A. M. & Klein, R. Met receptor signaling is required for sensory nerve development and HGF promotes axonal growth and survival of sensory neurons. Genes Dev. 11, 3341-3350 (1997).
111. Maina, F. et al. Multiple roles for hepatocyte growth factor in sympathetic neuron development. Neuron 20, 835-846 (1998).
112. Helmbacher, F. et al. Met signaling is required for recruitment of motor neurons to PEA3-positive motor neurons. Neuron 39, 767-777 (2003).
113. Maina, F. et al. Coupling Met to specific pathways results in distinct developmental outcomes. Mol. Cell 7, 1293-1306 (2001).
114. Sachs, M. et al. Essential role of Gab1 for signaling by the c-Met receptor in vivo. J. Cell Biol. 150, 1375-1384 (2000).
115. Schaeper, U. et al. Distinct requirements for Gab1 in Met and EGF receptor signaling in vivo. Proc. Natl Acad. Sci. USA 104, 15376-15381 (2007).
116. Debnath, J. & Brugge, J. S. Modelling glandular epithelial cancers in three-dimensional cultures. Nature Rev. Cancer 5, 675-688 (2005).
117. Rosário, M. & Birchmeier, W. How to make tubes: signaling by the Met receptor tyrosine kinase. Trends Cell Biol. 13, 328-335 (2003).
118. O'Brien, L. E. et al. ERK and MMPs sequentially regulate distinct stages of epithelial tubule development. Dev. Cell 7, 21-32 (2004).
119. Rosário, M. & Birchmeier, W. Making tubes: step by step. Dev. Cell 7, 3-5 (2004).
120. Leroy, P. & Mostov, K. E. Slug is required for cell survival during partial epithelial-mesenchymal transition of HGF-induced tubulogenesis. Mol. Biol. Cell 18, 1943-1952 (2007).
121. Rosenthal, E. L. et al. Role of the plasminogen activator and matrix metalloproteinase systems in epidermal growth factor- and scatter factor-stimulated invasion of carcinoma cells. Cancer Res. 58, 5221-5230 (1998).
122. Nabeshima, K. et al. Front-cell-specific expression of membrane-type 1 matrix metalloproteinase and gelatinase A during cohort migration of colon carcinoma cells induced by hepatocyte growth factor/ scatter factor. Cancer Res. 60, 3364-3369 (2000).
123. Monvoisin, A. et al. Involvement of matrix metalloproteinase type-3 in hepatocyte growth factor-induced invasion of human hepatocellular carcinoma cells. Int. J. Cancer 97, 157-162 (2002).
124. Miyazawa, K. et al. Molecular cloning and sequence analysis of cDNA for human hepatocyte growth factor. Biochem. Biophys. Res. Commun. 163, 967-973 (1989).
125. Huh, C. G. et al. Hepatocyte growth factor/c-met signaling pathway is required for efficient liver regeneration and repair. Proc. Natl Acad. Sci. USA 101, 4477-4482 (2004).
126. Borowiak, M. et al. Met provides essential signals for liver regeneration. Proc. Natl Acad. Sci. USA 101, 10608-10613 (2004).
127. Bard-Chapeau, E. A. et al. Concerted functions of Gab1 and Shp2 in liver regeneration and hepatoprotection. Mol. Cell. Biol. 26, 4664-4674 (2006).
128. Liu, Y. Hepatocyte growth factor in kidney fibrosis: therapeutic potential and mechanisms of action. Am. J. Physiol. Renal Physiol. 287, F7-F16 (2004).
129. Wynn, T. A. Cellular and molecular mechanisms of fibrosis. J. Pathol. 214, 199-210 (2008).
130. Ueki, T. et al. Hepatocyte growth factor gene therapy of liver cirrhosis in rats. Nature Med. 5, 226-230 (1999).
131. Yang, J., Dai, C. & Liu, Y. Hepatocyte growth factor suppresses renal interstitial myofibroblast activation and intercepts Smad signal transduction. Am. J. Pathol. 163, 621-632 (2003).
132. Dai, C. & Liu, Y. Hepatocyte growth factor antagonizes the profibrotic action of TGF-β1 in mesangial cells by stabilizing Smad transcriptional corepressor TGIF. J. Am. Soc. Nephrol. 15, 1402-1412 (2004).
133. Kim, W. H., Matsumoto, K., Bessho, K. & Nakamura, T. Growth inhibition and apoptosis in liver myofibroblasts promoted by hepatocyte growth factor leads to resolution from liver cirrhosis. Am. J. Pathol. 166, 1017-1028 (2005).
134. Blanpain, C. & Fuchs, E. Epidermal homeostasis: a balancing act of stem cells in the skin. Nature Rev. Mol. Cell Biol. 10, 207-217 (2009).
135. Chmielowiec, J. et al. c-Met is essential for wound healing in the skin. J. Cell Biol. 177, 151-162 (2007).
136. Pennacchietti, S. et al. Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell 3, 347-361 (2003).
137. Giordano, S. et al. A point mutation in the MET oncogene abrogates metastasis without affecting transformation. Proc. Natl Acad. Sci. USA 94, 13868-13872 (1997).
138. Bardelli, A. et al. Concomitant activation of pathways downstream of Grb2 and PI3-kinase is required for MET-mediated metastasis. Oncogene 18, 1139-1146 (1999).
139. Ma, P. C. et al. Downstream signalling and specific inhibition of c-Met/HGF pathway in small cell lung cancer: implications for tumour invasion. Br. J. Cancer 97, 368-377 (2007).
140. Schmidt, L. et al. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nature Genet. 16, 68-73 (1997).
141. Stella, G. M. et al. MET mutations in cancers of unknown primary origin. Hum. Mutat. 14 Oct 2010 (doi:10.1002/humu.21374).
142. Smolen, G. A. et al. Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752. Proc. Natl Acad. Sci. USA 103, 2316-2321 (2006).
143. McDermott, U. et al. Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling. Proc. Natl Acad. Sci. USA 104, 19936-19941 (2007).
144. Guo, A. et al. Signaling networks assembled by oncogenic EGFR and c-Met. Proc. Natl Acad. Sci. USA 105, 692-697 (2008).
145. Bertotti, A. et al. Only a subset of Met-activated pathways are required to sustain oncogene addiction. Sci. Signal. 2, Ra80 (2009).
146. Bertotti, A. et al. Inhibition of Src impairs the growth of Met-addicted gastric tumors. Clin. Cancer Res. 16, 3933-3943 (2010).
147. Amit, I. et al. A module of negative feedback regulators defines growth factor signaling. Nature Genet. 39, 503-512 (2007).
148. Jeffrey, K. L., Camps, M., Rommel, C. & Mackay, C. R. Targeting dual-specificity phosphatases: manipulating MAP kinase signalling and immune responses. Nature Rev. Drug Discov. 6, 391-403 (2007).
149. Kim, S. et al. MicroRNA mir199-a regulates the MET proto-oncogene and the downstream extracellular signal-regulated kinase 2 (ERK2). J. Biol. Chem. 283, 18158-18166 (2008).
150. Migliore, C. et al. MicroRNAs impair MET-mediated invasive growth. Cancer Res. 68, 10128-10136 (2008).
151. Taulli, R. et al. The muscle-specific microRNA miR-206 blocks human rhabdomyosarcoma growth in xenotransplanted mice by promoting myogenic differentiation. J. Clin. Invest. 11 9, 2366-2378 (2009).
152. Garofalo, M. et al. miR-221&222 regulate TRAIL resistance and enhance tumorigenicity through PTEN and TIMP3 downregulation. Cancer Cell 16, 498-509 (2009).
153. Fornari, F. et al. MiR-199a-3p regulates mTOR and c-Met to influence the doxorubicin sensitivity of human hepatocarcinoma cells. Cancer Res. 70, 5184-5193 (2010).
154. Bradbury, J. A two-pronged approach to the clinical use of HGF. Lancet 351, 272 (1998).
155. Basilico, C., Arnesano, A., Galluzzo, M., Comoglio, P. M. & Michieli, P. A high affinity hepatocyte growth factor-binding site in the immunoglobulin-like region of Met. J. Biol. Chem. 283, 21267-21277 (2008).
156. Stamos, J., Lazarus, R. A., Yao, X., Kirchhofer, D. & Wiesmann, C. Crystal structure of the HGF β-chain in complex with the Sema domain of the Met receptor. EMBO J. 23, 2325-2335 (2004).
157. Shima, N. et al. Tumor cytotoxic factor/hepatocyte growth factor from human fibroblasts: cloning of its cDNA, Purification and characterization of recombinant protein. Biochem. Biophys. Res. Commun. 180, 1151-1158 (1991).
158. Matteucci, E., Castoldi, R. & Desiderio, M. A. Hepatocyte growth factor induces pro-apoptotic genes in HepG2 hepatoma but not in B16-F1 melanoma cells. J. Cell. Physiol. 186, 387-396 (2001).
159. Mizuno, S., Matsumoto, K. & Nakamura, T. HGF reduces advancing lung fibrosis in mice: a potential role for MMP-dependent myofibroblast apoptosis. FASEB J. 19, 580-582 (2005).
160. Tacchini, L., De Ponti, C., Matteucci, E., Follis, R. & Desiderio, M. A. Hepatocyte growth factor-activated NF-κB regulates HIF-1 activity and ODC expression, Implicated in survival, Differently in different carcinoma cell lines. Carcinogenesis 25, 2089-2100 (2004).
161. Wang, X. et al. A mechanism of cell survival: sequestration of Fas by the HGF receptor Met. Mol. Cell 9, 411-421 (2002).
162. Tulasne, D. et al. Proapoptotic function of the Met tyrosine kinase receptor through caspase cleavage. Mol. Cell. Biol. 24, 10328-10339 (2004).
163. Foveau, B. et al. Amplification of apoptosis through sequential caspase cleavage of the Met tyrosine kinase receptor. Cell Death Differ. 14, 752-764 (2007).
164. Potempa, S. & Ridley, A. J. Activation of both MAP kinase and phosphatidylinositide 3-kinase by Ras is required for hepatocyte growth factor/scatter factor-induced adherens junction disassembly. Mol. Biol. Cell 9, 2185-2200 (1998).
165. Rahimi, N., Hung, W., Tremblay, E., Saulnier, R. & Elliott, B. c-Src kinase activity is required for hepatocyte growth factor-induced motility and anchorage-independent growth of mammary carcinoma cells. J. Biol. Chem. 273, 33714-33721 (1998).
166. Royal, I. & Park, M. Hepatocyte growth factor-induced scatter of Madin-Darby canine kidney cells requires phosphatidylinositol 3-kinase. J. Biol. Chem. 270, 27780-27787 (1995).
167. Khwaja, A., Lehmann, K., Marte, B. M. & Downward, J. Phosphoinositide 3-kinase induces scattering and tubulogenesis in epithelial cells through a novel pathway. J. Biol. Chem. 273, 18793-18801 (1998).
168. Sakkab, D. et al. Signaling of hepatocyte growth factor/scatter factor (HGF) to the small GTPase Rap1 via the large docking protein Gab1 and the adapter protein CRKL. J. Biol. Chem. 275, 10772-10778 (2000).
169. Xiao, G. H. et al. Anti-apoptotic signaling by hepatocyte growth factor/Met via the phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase pathways. Proc. Natl Acad. Sci. USA 98, 247-252 (2001).